Featured Article
Many cancer clinical trials are excluding people with the Duffy null blood group, common in people with African or Middle Eastern ancestry, due to low neutrophil levels.
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
Better Heart Health Early on May Offset Risk of Pregnancy-Related Hypertension
Good cardiovascular health in early pregnancy was linked to lower risk of hypertension even in women at genetic risk of the condition according to a new large scale study.
Five Features Underlie Immunotherapy Response
Five underlying features can predict a patient’s response to immunotherapy using checkpoint inhibitors, potentially widening their use and improving the personalization of cancer treatment.
Antibiotic Use Linked to Increased Risk of Inflammatory Bowel Disease
In a landmark study, researchers from Bar-Ilan University have uncovered critical insights into how antibiotic use increases the risk of inflammatory bowel disease (IBD) by reducing the production of a protective mucus layer in the gut.